{"title": "Borreliose: Epidemiologie, Erythema migrans", "author": "PHC Primary; Hospital Care; Philip Tarr; C\u00e9cile Lanz; Johannes Nemeth; Esther K\u00fcnzli; Michael Dapprich; Gisela Etter; Anne Meynard; Charles B\u00e9guelin; Axel J Schmid; Katia Boggian", "url": "https://phc.swisshealthweb.ch/de/article/doi/phc-d.2022.10573/", "hostname": "swisshealthweb.ch", "description": "Die Borreliose wird jedes Fr\u00fchjahr erneut zum Thema, wenn Waldspazierg\u00e4ngerinnen und -spazierg\u00e4nger einen Zeckenstich als Souvenir nach Hause bringen. In drei Teilen berichten wir \u00fcber diese komplexe Infektion und ihre spannenden epidemiologischen und sozialpsychologischen Zusammenh\u00e4nge.", "sitename": "Philip Tarr,C\u00e9cile Lanz,Johannes Nemeth,Esther K\u00fcnzli,Michael Dapprich,Gisela Etter,Anne Meynard,Charles B\u00e9guelin,Axel J. Schmid,Katia Boggian", "date": "2022-04-06", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "1. Bundesamt f\u00fcr Gesundheit (BAG). Zecken\u00fcbertragene Krankheiten - Lagebericht Schweiz. 2020 06.11.2020 [cited 2021 05.04.2021]; Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/zeckenuebertragene-krankheiten.html.\n2. Altpeter, E., et al., Tick related diseases in Switzerland, 2008 to 2011. Swiss Med Wkly, 2013. 143: p. w13725.\n3. Evison, J., et al., Abkl\u00e4rung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft f\u00fcr Infektiologie. Teil 1: Epidemiologie und Diagnostik. Schweiz \u00c4rzteztg, 2005. 86(41).\n4. Evison, J., et al., Abkl\u00e4rung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft f\u00fcr Infektiologie. Teil 2: Klinik und Therapie. Schweiz \u00c4rzteztg, 2005. 86(42).\n5. Evison, J., et al., Abkl\u00e4rung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft f\u00fcr Infektiologie. Teil 3: Pr\u00e4vention, Schwangerschaft, Immundefizienz, Post-Lyme-Syndrom. Schweiz \u00c4rzteztg, 2005. 86(43).\n6. Schweizerische Gesellschaft Infektiologie (SGInf). SSI Guidelines: Borrelien, Lyme Erkrankung. 2020 [cited 2021 19.03.2021]; Available from: https://ssi.guidelines.ch/guideline/2274.\n7. Mygland, A., et al., EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol, 2010. 17(1): p. 8-16, e1-4.\n8. Rauer, S., et al. Neuroborreliose, S3-Leitlinie. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie 2018 03.11.2020 [cited 2021 02.05.2021]; Available from: https://dgn.org/wp-content/uploads/2013/01/030071_LL_Neuroborreliose_2018.pdf.\n9. Lantos, P.M., et al., Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis, 2021. 72(1): p. e1-e48.\n10. Stanek, G., et al., Lyme borreliosis. Lancet, 2012. 379(9814): p. 461-73.\n11. Wormser, G.P., Clinical practice. Early Lyme disease. N Engl J Med, 2006. 354(26): p. 2794-801.\n12. Luft, B.J., et al., Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med, 1996. 124(9): p. 785-91.\n13. Enkelmann, J., et al., Incidence of notified Lyme borreliosis in Germany, 2013-2017. Sci Rep, 2018. 8(1): p. 14976.\n14. Septfons, A., et al., Epidemiology of Lyme borreliosis through two surveillance systems: the national Sentinelles GP network and the national hospital discharge database, France, 2005 to 2016. Euro Surveill, 2019. 24(11).\n15. Schwartz, A.M., et al., Surveillance for Lyme Disease - United States, 2008-2015. MMWR Surveill Summ, 2017. 66(22): p. 1-12.\n16. Programmkommission. Das Sentinella-Meldesystem. [cited 2021 05.04.2021]; Available from: http://www.sentinella.ch/de/info.\n17. Gern, L., [The biology of the Ixodes ricinus tick]. Ther Umsch, 2005. 62(11): p. 707-12.\n18. Bundesamt f\u00fcr Gesundheit (BAG). Zecken\u00fcbertragene Krankheiten. 2021 15.04.2021 [cited 2021 21.09.2021]; Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/zeckenuebertragene-krankheiten.html.\n19. Frischknecht, M., et al., Tularemia: an experience of 13 cases including a rare myocarditis in a referral center in Eastern Switzerland (Central Europe) and a review of the literature. Infection, 2019. 47(5): p. 683-695.\n20. Pharmasuisse, Die Wissenschaftliche Zentralstelle (WIZE) antwortet: Zeckentests - Sinn oder Unsinn? . PharmaJournal, 2013. 08.\n21. Centre national de r\u00e9f\u00e9rence pour les maladies transmises par les tiques (CNRT). Zeckentests zum Nachweis von Borrelien: Negative Stellungsnahme des CNRT zu deren Verwendung. 2013 [cited 2021 05.04.2021]; Available from: https://www.labor-spiez.ch/pdf/de/die/bio/Stellungnahme_CNRT_Zeckenschnelltest_de.pdf.\n22. Aeschlimann, A., et al., B. burgdorferi in Switzerland. Zentralbl Bakteriol Mikrobiol Hyg A, 1987. 263(3): p. 450-8.\n23. Bundesamt f\u00fcr Gesundheit (BAG). Bundesamt f\u00fcr Gesundheit (BAG) - Flyer Zecken. 06/2019 [cited 2021 17.03.2021].\n24. Lindgren, E., L. T\u00e4lleklint, and T. Polfeldt, Impact of climatic change on the northern latitude limit and population density of the disease-transmitting European tick Ixodes ricinus. Environ Health Perspect, 2000. 108(2): p. 119-23.\n25. Jouda, F., J.L. Perret, and L. Gern, Ixodes ricinus density, and distribution and prevalence of Borrelia burgdorferi sensu lato infection along an altitudinal gradient. J Med Entomol, 2004. 41(2): p. 162-9.\n26. Z\u00fcrcher Hochschule f\u00fcr Angewandte Wissenschaften (ZHAW). Schweizer Zeckenstichkarte: Mehr Zeckenstiche in dicht besiedelten Regionen [Medienmitteilung] 2017 10.04.2017 [cited 2021 09.07.2021]; Available from: https://www.zhaw.ch/storage/hochschule/medien/news/170410-medienmitteilung-zeckenstichkarte-de.pdf.\n27. Herrmann, C. and L. Gern, Search for blood or water is influenced by Borrelia burgdorferi in Ixodes ricinus. Parasit Vectors, 2015. 8: p. 6.\n28. Jaenson, T.G., et al., Changes in the geographical distribution and abundance of the tick Ixodes ricinus during the past 30 years in Sweden. Parasit Vectors, 2012. 5: p. 8.\n29. Dautel, H., et al., Winter activity of Ixodes ricinus in a Berlin forest. International Journal of Medical Microbiology, 2008. 298: p. 50-54.\n30. Hauser, G., et al., Influence of climatic factors on Ixodes ricinus nymph abundance and phenology over a long-term monthly observation in Switzerland (2000-2014). Parasit Vectors, 2018. 11(1): p. 289.\n31. Perret, J.L., et al., Influence of saturation deficit and temperature on Ixodes ricinus tick questing activity in a Lyme borreliosis-endemic area (Switzerland). Parasitol Res, 2000. 86(7): p. 554-7.\n32. Oechslin, C.P., et al., Prevalence of tick-borne pathogens in questing Ixodes ricinus ticks in urban and suburban areas of Switzerland. Parasit Vectors, 2017. 10(1): p. 558.\n33. Maetzel, D., W.A. Maier, and H. Kampen, Borrelia burgdorferi infection prevalences in questing Ixodes ricinus ticks (Acari: Ixodidae) in urban and suburban Bonn, western Germany. Parasitol Res, 2005. 95(1): p. 5-12.\n34. Rizzoli, A., et al., Ixodes ricinus and Its Transmitted Pathogens in Urban and Peri-Urban Areas in Europe: New Hazards and Relevance for Public Health. Front Public Health, 2014. 2: p. 251.\n35. Mejlon, H.A. and T.G.T. Jaenson, Questing behaviour of Ixodes ricinus ticks (Acari: Ixodidae). Experimental & Applied Acarology, 1997. 21(12): p. 747-754.\n36. Gigon, F., Biologie d'Ixodes ricinus L. sur le Plateau Suisse - une contribution \u00e0 l'\u00e9cologie de ce vecteur. PhD thesis, University of Neuch\u00e2tel, Biology Department, 1985.\n37. H\u00fcgli, D., et al., Tick bites in a Lyme borreliosis highly endemic area in Switzerland. Int J Med Microbiol, 2009. 299(2): p. 155-60.\n38. Cull, B., et al., Seasonality and anatomical location of human tick bites in the United Kingdom. Zoonoses Public Health, 2020. 67(2): p. 112-121.\n39. Jones, E.H., et al., Pet ownership increases human risk of encountering ticks. Zoonoses Public Health, 2018. 65(1): p. 74-79.\n40. Herrin, B.H., et al., Canine and human infection with Borrelia burgdorferi in the New York City metropolitan area. Parasit Vectors, 2018. 11(1): p. 187.\n41. Little, S.E., et al., Lyme borreliosis in dogs and humans in the USA. Trends Parasitol, 2010. 26(4): p. 213-8.\n42. Curran, K.L. and D. Fish, Increased risk of Lyme disease for cat owners. N Engl J Med, 1989. 320(3): p. 183.\n43. Robert Koch Institut (RKI). Lyme-Borreliose, RKI-Ratgeber. 1999 25.04.2019 [cited 2022 01.02.2022]; Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_LymeBorreliose.html.\n44. Divers, T.J., et al., Borrelia burgdorferi Infection and Lyme Disease in North American Horses: A Consensus Statement. J Vet Intern Med, 2018. 32(2): p. 617-632.\n45. Piesman, J., et al., Duration of tick attachment and Borrelia burgdorferi transmission. J Clin Microbiol, 1987. 25(3): p. 557-8.\n46. Kahl, O., et al., Risk of infection with Borrelia burgdorferi sensu lato for a host in relation to the duration of nymphal Ixodes ricinus feeding and the method of tick removal. Zentralbl Bakteriol, 1998. 287(1-2): p. 41-52.\n47. Crippa, M., O. Rais, and L. Gern, Investigations on the mode and dynamics of transmission and infectivity of Borrelia burgdorferi sensu stricto and Borrelia afzelii in Ixodes ricinus ticks. Vector Borne Zoonotic Dis, 2002. 2(1): p. 3-9.\n48. des Vignes, F., et al., Effect of tick removal on transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs. J Infect Dis, 2001. 183(5): p. 773-8.\n49. Hermance, M.E. and S. Thangamani, Tick Virus Host Interactions at the Cutaneous Interface: The Nidus of Flavivirus Transmission. Viruses, 2018. 10(7).\n50. Lindquist, L. and O. Vapalahti, Tick-borne encephalitis. Lancet, 2008. 371(9627): p. 1861-71.\n51. Jouda, F., J.L. Perret, and L. Gern, Density of questing Ixodes ricinus nymphs and adults infected by Borrelia burgdorferi sensu lato in Switzerland: spatio-temporal pattern at a regional scale. Vector Borne Zoonotic Dis, 2004. 4(1): p. 23-32.\n52. Burri, C., et al., Ixodes ricinus density and infection prevalence of Borrelia burgdorferi sensu lato along a North-facing altitudinal gradient in the Rh\u00f4ne Valley (Switzerland). Vector Borne Zoonotic Dis, 2007. 7(1): p. 50-8.\n53. Mor\u00e1n Cadenas, F., et al., Phenology of Ixodes ricinus and infection with Borrelia burgdorferi sensu lato along a north- and south-facing altitudinal gradient on Chaumont Mountain, Switzerland. J Med Entomol, 2007. 44(4): p. 683-93.\n54. Zhioua, E., et al., Longitudinal study of Lyme borreliosis in a high risk population in Switzerland. Parasite, 1998. 5(4): p. 383-6.\n55. Nahimana, I., et al., Risk of Borrelia burgdorferi infection in western Switzerland following a tick bite. Eur J Clin Microbiol Infect Dis, 2004. 23(8): p. 603-8.\n56. Fahrer, H., et al., The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a population at risk. J Infect Dis, 1991. 163(2): p. 305-10.\n57. Kulkarni, S.M. and V.M. Naik, Laboratory evaluation of six repellents against some Indian ticks. Indian J Med Res, 1985. 82: p. 14-8.\n58. Schreck, C.E., D. Fish, and T.P. McGovern, Activity of repellents applied to skin for protection against Amblyomma americanum and Ixodes scapularis ticks (Acari: Ixodidae). J Am Mosq Control Assoc, 1995. 11(1): p. 136-40.\n59. Schreck, C.E., E.L. Snoddy, and A. Spielman, Pressurized sprays of permethrin or deet on military clothing for personal protection against Ixodes dammini (Acari: Ixodidae). J Med Entomol, 1986. 23(4): p. 396-9.\n60. Solberg, V.B., et al., Field evaluation of deet and a piperidine repellent (AI3-37220) against Amblyomma americanum (Acari: Ixodidae). J Med Entomol, 1995. 32(6): p. 870-5.\n61. Staub, D., et al., Effectiveness of a repellent containing DEET and EBAAP for preventing tick bites. Wilderness Environ Med, 2002. 13(1): p. 12-20.\n62. Maibach, H.I., A.A. Khan, and W. Akers, Use of insect repellents for maximum efficacy. Arch Dermatol, 1974. 109(1): p. 32-5.\n63. American Academy of Pediatrics, American Academy of Pediatrics. Committee on Infecious Diseases. Prevention of Lyme disease. Pediatrics, 2000. 105(1 Pt 1): p. 142-7.\n64. Osimitz, T.G., et al., Adverse events associated with the use of insect repellents containing N,N-diethyl-m-toluamide (DEET). Regul Toxicol Pharmacol, 2010. 56(1): p. 93-9.\n65. B\u00fcchel, K., et al., Repellent efficacy of DEET, Icaridin, and EBAAP against Ixodes ricinus and Ixodes scapularis nymphs (Acari, Ixodidae). Ticks Tick Borne Dis, 2015. 6(4): p. 494-8.\n66. Mutebi John-Paul, G.J.E.C.f.D.C.a.P.C. Mosquitoes, Ticks & other Arthropods. Travelers' Health, Yellow Book 2020 07/2019 [cited 2021 27.04.2021]; Available from: https://wwwnc.cdc.gov/travel/yellowbook/2020/noninfectious-health-risks/mosquitoes-ticks-and-other-arthropods.\n67. Wang, T. and X. Gu, In vitro percutaneous permeation of the repellent DEET and the sunscreen oxybenzone across human skin. J Pharm Pharm Sci, 2007. 10(1): p. 17-25.\n68. Yiin, L.M., J.N. Tian, and C.C. Hung, Assessment of dermal absorption of DEET-containing insect repellent and oxybenzone-containing sunscreen using human urinary metabolites. Environ Sci Pollut Res Int, 2015. 22(9): p. 7062-70.\n69. Hexsel, C.L., et al., Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products. J Am Acad Dermatol, 2008. 59(2): p. 316-23.\n70. Montemarano, A.D., et al., Insect repellents and the efficacy of sunscreens. Lancet, 1997. 349(9066): p. 1670-1.\n71. Murphy, M.E., et al., The effect of sunscreen on the efficacy of insect repellent: a clinical trial. J Am Acad Dermatol, 2000. 43(2 Pt 1): p. 219-22.\n72. Evans, S.R., G.W. Korch, Jr., and M.A. Lawson, Comparative field evaluation of permethrin and deet-treated military uniforms for personal protection against ticks (Acari). J Med Entomol, 1990. 27(5): p. 829-34.\n73. Vaughn, M.F., et al., Long-lasting permethrin impregnated uniforms: A randomized-controlled trial for tick bite prevention. Am J Prev Med, 2014. 46(5): p. 473-80.\n74. Faulde, M.K., et al., Pilot study assessing the effectiveness of factory-treated, long-lasting permethrin-impregnated clothing for the prevention of tick bites during occupational tick exposure in highly infested military training areas, Germany. Parasitol Res, 2015. 114(2): p. 671-8.\n75. Mitchell, C., et al., Protective Effectiveness of Long-Lasting Permethrin Impregnated Clothing Against Tick Bites in an Endemic Lyme Disease Setting: A Randomized Control Trial Among Outdoor Workers. J Med Entomol, 2020. 57(5): p. 1532-1538.\n76. Connally, N.P., et al., Impact of Wearing and Washing/Drying of Permethrin-Treated Clothing on Their Contact Irritancy and Toxicity for Nymphal Ixodes scapularis (Acari: Ixodidae) Ticks. J Med Entomol, 2019. 56(1): p. 199-214.\n77. Antibrumm. Kokos\u00f6l, Lavendel oder Schwarzk\u00fcmmel\u00f6l: Was taugen Hausmittel gegen Zecken wirklich? [cited 2021 17.03.2021]; Available from: https://www.antibrumm.ch/zecken/hausmittel-gegen-zecken/.\n78. Roland, E.H., J.E. Jan, and J.M. Rigg, Toxic encephalopathy in a child after brief exposure to insect repellents. Can Med Assoc J, 1985. 132(2): p. 155-6.\n79. Lipscomb, J.W., J.E. Kramer, and J.B. Leikin, Seizure following brief exposure to the insect repellent N,N-diethyl-m-toluamide. Ann Emerg Med, 1992. 21(3): p. 315-7.\n80. Gryboski, J., D. Weinstein, and N.K. Ordway, Toxic encephalopathy apparently related to the use of an insect repellent. N Engl J Med, 1961. 264: p. 289-91.\n81. Bundesamt f\u00fcr Gesundheit (BAG). FAQ - Zecken und durch Zecken \u00fcbertragene Krankheitserreger. 2019 15.11.2019 [cited 2021 21.03.2021]; Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/zeckenuebertragene-krankheiten.html.\n82. Antibrumm. DEET, Icaridin oder Citriodiol - den passenden Wirkstoff gegen M\u00fccken finden. [cited 2021 17.03.2021]; Available from: https://www.antibrumm.ch/produkte/wirkstoffe/.\n83. Gardulf, A., I. Wohlfart, and R. Gustafson, A prospective cross-over field trial shows protection of lemon eucalyptus extract against tick bites. J Med Entomol, 2004. 41(6): p. 1064-7.\n84. Abdel-Ghaffar, F., S. Al-Quraishy, and H. Mehlhorn, Length of tick repellency depends on formulation of the repellent compound (icaridin = Saltidin\u00ae): tests on Ixodes persulcatus and Ixodes ricinus placed on hands and clothes. Parasitol Res, 2015. 114(8): p. 3041-5.\n85. Semmler, M., et al., Comparison of the tick repellent efficacy of chemical and biological products originating from Europe and the USA. Parasitol Res, 2011. 108(4): p. 899-904.\n86. Lupi, E., C. Hatz, and P. Schlagenhauf, The efficacy of repellents against Aedes, Anopheles, Culex and Ixodes spp. - a literature review. Travel Med Infect Dis, 2013. 11(6): p. 374-411.\n87. McGready, R., et al., Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. Am J Trop Med Hyg, 2001. 65(4): p. 285-9.\n88. McKinney, K.L., et al., Malaria in the pregnant traveler. J Travel Med, 2020. 27(4).\n89. Bundesamt f\u00fcr Gesundheit (BAG). Borreliose / Lyme-Krankheit. 2021 26.03.2021 [cited 2021 25.05.2021]; Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/borreliose-lyme-krankheit.html.\n90. Steere, A.C., et al., Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med, 1998. 339(4): p. 209-15.\n91. Kamradt, T., Lyme disease and current aspects of immunization. Arthritis Research & Therapy, 2001. 4(1): p. 20.\n92. Sigal, L.H., et al., A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med, 1998. 339(4): p. 216-22.\n93. Oliveira, C.R., et al., Clinical Effectiveness of Lyme Vaccine: A Matched Case-Control Study. Open Forum Infect Dis, 2021. 8(8): p. ofab142.\n94. Plotkin, S.A., Need for a New Lyme Disease Vaccine. New England Journal of Medicine, 2016. 375(10): p. 911-913.\n95. Poland, G.A., Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis, 2011. 52 Suppl 3: p. s253-8.\n96. Nadelman, R.B., et al., Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med, 2001. 345(2): p. 79-84.\n97. Warshafsky, S., et al., Efficacy of antibiotic prophylaxis for the prevention of Lyme disease: an updated systematic review and meta-analysis. J Antimicrob Chemother, 2010. 65(6): p. 1137-44.\n98. Harms, M.G., et al., A single dose of doxycycline after an ixodes ricinus tick bite to prevent Lyme borreliosis: An open-label randomized controlled trial. J Infect, 2021. 82(1): p. 98-104.\n99. Nilsson, K., et al., A comprehensive clinical and laboratory evaluation of 224 patients with persistent symptoms attributed to presumed tick-bite exposure. PLoS One, 2021. 16(3): p. e0247384.\n100. Mavin, S., E.J. Watson, and R. Evans, Distribution and presentation of Lyme borreliosis in Scotland - analysis of data from a national testing laboratory. J R Coll Physicians Edinb, 2015. 45(3): p. 196-200.\n101. Burke, G., et al., Hypersensitivity to ticks and Lyme disease risk. Emerg Infect Dis, 2005. 11(1): p. 36-41.\n102. Van Nunen, S.A., et al., An association between tick bite reactions and red meat allergy in humans. Med J Aust, 2009. 190(9): p. 510-1.\n103. Altshuler, E., et al., Mammalian meat allergy emerges after tick bite: the alpha-gal syndrome. BMJ Case Rep, 2021. 14(11).\n104. Young, I., et al., Tick exposures and alpha-gal syndrome: A systematic review of the evidence. Ticks Tick Borne Dis, 2021. 12(3): p. 101674.\n105. Kennedy, J.L., et al., Galactose-\u03b1-1,3-galactose and delayed anaphylaxis, angioedema, and urticaria in children. Pediatrics, 2013. 131(5): p. e1545-52.\n106. Centers for Disease Control and Prevention (CDC). Alpha-gal Syndrome. 2021 18.10.2021 [cited 2022 01.02.2022]; Available from: https://www.cdc.gov/ticks/alpha-gal/index.html.\n107. Platts-Mills, T.A.E., et al., Diagnosis and Management of Patients with the \u03b1-Gal Syndrome. J Allergy Clin Immunol Pract, 2020. 8(1): p. 15-23.e1.\n108. Kim, M.S., et al., IgE to galactose-\u03b1-1,3-galactose wanes over time in patients who avoid tick bites. J Allergy Clin Immunol Pract, 2020. 8(1): p. 364-367.e2.\n109. Tibbles, C.D. and J.A. Edlow, Does this patient have erythema migrans? Jama, 2007. 297(23): p. 2617-27.\n110. Nadelman, R.B., Erythema migrans. Infect Dis Clin North Am, 2015. 29(2): p. 211-39.\n111. Edlow, J.A., Erythema migrans. Med Clin North Am, 2002. 86(2): p. 239-60.\n112. Constantin, C., et al., [Erythema migrans with multiple lesions]. Ann Dermatol Venereol, 2000. 127(5): p. 513-6.\n113. Branda, J.A. and A.C. Steere, Laboratory Diagnosis of Lyme Borreliosis. Clin Microbiol Rev, 2021. 34(2).\n114. Engstrom, S.M., E. Shoop, and R.C. Johnson, Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microbiol, 1995. 33(2): p. 419-27.\n115. Aguero-Rosenfeld, M.E., et al., Diagnosis of lyme borreliosis. Clin Microbiol Rev, 2005. 18(3): p. 484-509.\n116. Wormser, G.P., et al., Impact of clinical variables on Borrelia burgdorferi-specific antibody seropositivity in acute-phase sera from patients in North America with culture-confirmed early Lyme disease. Clin Vaccine Immunol, 2008. 15(10): p. 1519-22.\n117. Steere, A.C., et al., Prospective study of serologic tests for lyme disease. Clin Infect Dis, 2008. 47(2): p. 188-95.\n118. Nadelman, R.B. and G.P. Wormser, Lyme borreliosis. Lancet, 1998. 352(9127): p. 557-65.\n119. Stanek, G. and F. Strle, Lyme borreliosis. Lancet, 2003. 362(9396): p. 1639-47.\n120. Stupica, D., et al., Comparison of Clinical Course and Treatment Outcome for Patients With Early Disseminated or Early Localized Lyme Borreliosis. JAMA Dermatol, 2018. 154(9): p. 1050-1056.\n121. Eliassen, K.E., et al., Symptom load and general function among patients with erythema migrans: a prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice. Scand J Prim Health Care, 2017. 35(1): p. 75-83.\n122. Wormser, G.P., et al., Prospective Evaluation of the Frequency and Severity of Symptoms in Lyme Disease Patients With Erythema Migrans Compared With Matched Controls at Baseline, 6 Months, and 12 Months. Clin Infect Dis, 2020. 71(12): p. 3118-3124.\n123. Nadelman, R.B., et al., Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med, 1992. 117(4): p. 273-80.\n124. Luger, S.W., et al., Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother, 1995. 39(3): p. 661-7.\n125. Strle, F., et al., Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection, 1993. 21(2): p. 83-8.\n126. Wormser, G.P., D. McKenna, and J. Nowakowski, Management approaches for suspected and established Lyme disease used at the Lyme disease diagnostic center. Wien Klin Wochenschr, 2018. 130(15-16): p. 463-467.\n127. Strle, F., et al., Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from cerebrospinal fluid. Clin Infect Dis, 2006. 43(6): p. 704-10.\n128. Ogrinc, K., et al., Suspected early Lyme neuroborreliosis in patients with erythema migrans. Clin Infect Dis, 2013. 57(4): p. 501-9.\n129. Wormser, G.P. and J.J. Halperin, Toward a better understanding of European lyme neuroborreliosis. Clin Infect Dis, 2013. 57(4): p. 510-2.\n130. Steere, A.C., et al., The early clinical manifestations of Lyme disease. Ann Intern Med, 1983. 99(1): p. 76-82.\n131. Wormser, G.P., et al., Patients with Erythema Migrans: Characterizing the Impact of Initiation of Antibiotic Therapy Prior to Study Enrollment. Antimicrob Agents Chemother, 2020. 65(1).\n132. Strle, F., et al., Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection, 1996. 24(1): p. 64-8.\n133. Wormser, G.P., et al., Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 2003. 138(9): p. 697-704.\n134. Cerar, D., et al., Subjective symptoms after treatment of early Lyme disease. Am J Med, 2010. 123(1): p. 79-86.\n135. Seltzer, E.G., et al., Long-term outcomes of persons with Lyme disease. Jama, 2000. 283(5): p. 609-16.\n136. Kalish, R.A., et al., Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis, 2001. 33(6): p. 780-5.\n137. Feder, H.M., Jr., et al., Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin Infect Dis, 1992. 15(5): p. 788-93.\n138. Glatz, M., et al., Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients. Arch Dermatol, 2006. 142(7): p. 862-8.\n139. Berglund, J., et al., An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med, 1995. 333(20): p. 1319-27.\n140. Mayer, W., et al., Persistent atrioventricular block in Lyme borreliosis. Klin Wochenschr, 1990. 68(8): p. 431-5.\n141. Steere, A.C., R.T. Schoen, and E. Taylor, The clinical evolution of Lyme arthritis. Ann Intern Med, 1987. 107(5): p. 725-31.\n142. Arvikar, S.L. and A.C. Steere, Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am, 2015. 29(2): p. 269-80.\n143. Corre, C., et al., Lyme arthritis in Western Europe: a multicentre retrospective study. Eur J Clin Microbiol Infect Dis, 2021.\n144. Grillon, A., et al., Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. Semin Arthritis Rheum, 2019. 48(6): p. 1105-1112.\n145. Nocton, J.J., et al., Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med, 1994. 330(4): p. 229-34.\n146. Priem, S., et al., An optimized PCR leads to rapid and highly sensitive detection of Borrelia burgdorferi in patients with Lyme borreliosis. J Clin Microbiol, 1997. 35(3): p. 685-90.\n147. Jaulhac, B., et al., Detection of Borrelia burgdorferi by DNA amplification in synovial tissue samples from patients with lyme arthritis. Arthritis & Rheumatism, 1996. 39(5): p. 736-745.\n148. Friberger Pajalic, K., A. Turkiewicz, and M. Englund, Update on the risks of complications after knee arthroscopy. BMC Musculoskelet Disord, 2018. 19(1): p. 179.\n149. Mayr, H.O. and A. Stoehr, [Complications of knee arthroscopy]. Orthopade, 2016. 45(1): p. 4-12.\n150. Lawson, J.P. and D.W. Rahn, Lyme disease and radiologic findings in Lyme arthritis. AJR Am J Roentgenol, 1992. 158(5): p. 1065-9.\n151. Flemming, D.J., et al., MR imaging assessment of arthritis of the knee. Magn Reson Imaging Clin N Am, 2014. 22(4): p. 703-24.\n152. Steere, A.C., Treatment of Lyme Arthritis. J Rheumatol, 2019. 46(8): p. 871-873.\n153. Steere, A.C., et al., Treatment of Lyme arthritis. Arthritis Rheum, 1994. 37(6): p. 878-88.\n154. Nemeth, J., et al., Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly, 2016. 146: p. w14353.\n155. Lochhead, R.B., et al., Lyme arthritis: linking infection, inflammation and autoimmunity. Nat Rev Rheumatol, 2021. 17(8): p. 449-461.\n156. Renaud, I., C. Cachin, and J.C. Gerster, Good outcomes of Lyme arthritis in 24 patients in an endemic area of Switzerland. Joint Bone Spine, 2004. 71(1): p. 39-43.\n157. Steere, A.C. and S.M. Angelis, Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum, 2006. 54(10): p. 3079-86.\n158. Scheffold, N., et al., Lyme carditis--diagnosis, treatment and prognosis. Dtsch Arztebl Int, 2015. 112(12): p. 202-8.\n159. Halperin, J.J., Neuroborreliosis (Nervous System Lyme Disease). Curr Treat Options Neurol, 1999. 1(2): p. 139-146.\n160. Hansen, K. and A.M. Lebech, The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain, 1992. 115 ( Pt 2): p. 399-423.\n161. Oschmann, P., et al., Stages and syndromes of neuroborreliosis. J Neurol, 1998. 245(5): p. 262-72.\n162. Dotevall, L. and L. Hagberg, Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis, 1999. 28(3): p. 569-74.\n163. Djukic, M., et al., Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. J Neurol, 2012. 259(4): p. 630-6.\n164. Kaiser, R., Neuroborreliosis. J Neurol, 1998. 245(5): p. 247-55.\n165. Kindstrand, E., et al., Peripheral neuropathy in acrodermatitis chronica atrophicans - a late Borrelia manifestation. Acta Neurol Scand, 1997. 95(6): p. 338-45.\n166. Wormser, G.P., et al., Lack of Convincing Evidence that Borrelia burgdorferi Infection Causes Either Alzheimer's Disease or Lewy Body Dementia. Clin Infect Dis, 2021.\n167. Halperin, J.J., Lyme neuroborreliosis. Curr Opin Infect Dis, 2019. 32(3): p. 259-264.\n168. Lj\u00f8stad, U., T. Skarpaas, and A. Mygland, Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis. Eur J Neurol, 2007. 14(8): p. 873-6.\n169. Blanc, F., et al., Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology, 2007. 69(10): p. 953-8.\n170. Reiber, H., C.B. Ressel, and A. Spreer, Diagnosis of neuroborreliosis \u2013 Improved knowledge base for qualified antibody analysis and cerebrospinal fluid data pattern related interpretations. Neurology, Psychiatry and Brain Research, 2013. 19(4): p. 159-169.\n171. Hansen, K. and A.M. Lebech, Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of Borrelia burgdorferi--specific immunoglobulin G, A, and M. Ann Neurol, 1991. 30(2): p. 197-205.\n172. Strle, F., A.J. Henningsson, and K. Strle, Diagnostic Utility of CXCL13 in Lyme Neuroborreliosis. Clin Infect Dis, 2021. 72(10): p. 1727-1729.\n173. Knudtzen, F.C., et al., Characteristics and Clinical Outcome of Lyme Neuroborreliosis in a High Endemic Area, 1995-2014: A Retrospective Cohort Study in Denmark. Clin Infect Dis, 2017. 65(9): p. 1489-1495.\n174. Nordberg, C.L., et al., Lyme neuroborreliosis in adults: A nationwide prospective cohort study. Ticks Tick Borne Dis, 2020. 11(4): p. 101411.\n175. Theel, E.S., et al., Limitations and Confusing Aspects of Diagnostic Testing for Neurologic Lyme Disease in the United States. J Clin Microbiol, 2019. 57(1).\n176. Lebech, A.M., et al., Diagnostic value of PCR for detection of Borrelia burgdorferi DNA in clinical specimens from patients with erythema migrans and Lyme neuroborreliosis. Mol Diagn, 2000. 5(2): p. 139-50.\n177. Cerar, T., et al., Validation of cultivation and PCR methods for diagnosis of Lyme neuroborreliosis. J Clin Microbiol, 2008. 46(10): p. 3375-9.\n178. Halperin, J.J., et al., Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2007. 69(1): p. 91-102.\n179. Avellan, S. and D. Bremell, Adjunctive Corticosteroids for Lyme Neuroborreliosis Peripheral Facial Palsy-A Prospective Study With Historical Controls. Clin Infect Dis, 2021. 73(7): p. 1211-1215.\n180. Hammers-Berggren, S., et al., Borrelia burgdorferi-specific intrathecal antibody production in neuroborreliosis: a follow-up study. Neurology, 1993. 43(1): p. 169-75.\n181. Drack, F.D. and M. Weissert, Outcome of peripheral facial palsy in children - a catamnestic study. Eur J Paediatr Neurol, 2013. 17(2): p. 185-91.\n182. Strle, F., et al., Treatment of borrelial lymphocytoma. Infection, 1996. 24(1): p. 80-4.\n183. Moter, S.E., et al., Detection of Borrelia burgdorferi sensu lato in lesional skin of patients with erythema migrans and acrodermatitis chronica atrophicans by ospA-specific PCR. J Clin Microbiol, 1994. 32(12): p. 2980-8.\n184. Gade, A., et al. Acrodermatitis Chronica Atrophicans. StatPearls 2021 15.04.2021 [cited 2021 30.10.2021]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK563289/.\n185. Bundesamt f\u00fcr Gesundheit (BAG). Zecken\u00fcbertragene Krankheiten. 2021 15.04.2021 [cited 2021 09.07.2021]; Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/zeckenuebertragene-krankheiten.html.\n186. Loutan, L., et al., [Human babesiosis: first case report in Switzerland]. Rev Med Suisse Romande, 1994. 114(2): p. 111-6.\n187. Vannier, E.G., et al., Babesiosis. Infect Dis Clin North Am, 2015. 29(2): p. 357-70.\n188. Wormser, G.P., et al., Differences and similarities between culture-confirmed human granulocytic anaplasmosis and early lyme disease. J Clin Microbiol, 2013. 51(3): p. 954-8.\n189. Bogdan, C., B.U. Baumgarten, and M. R\u00f6llinghoff, Ehrlichien: Durch Zecken \u00fcbertragbare Erreger. Dtsch Arztebl International, 2000. 97(38): p. A-2456.\n190. Aguero-Rosenfeld, M.E., Laboratory aspects of tick-borne diseases: lyme, human granulocytic ehrlichiosis and babesiosis. Mt Sinai J Med, 2003. 70(3): p. 197-206.\n191. Fischer, S., et al., High prevalence of Rickettsia helvetica in wild small mammal populations in Germany. Ticks Tick Borne Dis, 2018. 9(3): p. 500-505.\n192. Oteo, J.A. and A. Portillo, Tick-borne rickettsioses in Europe. Ticks Tick Borne Dis, 2012. 3(5-6): p. 271-8.\n193. Baumann, D., et al., [Fever after a tick bite: clinical manifestations and diagnosis of acute tick bite-associated infections in northeastern Switzerland]. Dtsch Med Wochenschr, 2003. 128(19): p. 1042-7.\n194. Bundesamt f\u00fcr Gesundheit (BAG). Tular\u00e4mie / Hasenpest. 22.11.2019 [cited 2021 28.05.2021]; Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/tularaemie.html.\n195. Faber, M., et al., Tularemia in Germany-A Re-emerging Zoonosis. Front Cell Infect Microbiol, 2018. 8: p. 40.\n196. Maurin, M. and M. Gyuranecz, Tularaemia: clinical aspects in Europe. Lancet Infect Dis, 2016. 16(1): p. 113-124.\n197. World Health Organization (WHO). WHO Guidelines on Tularaemia. 2007 [cited 2021 28.05.2021]; Available from: https://www.who.int/csr/resources/publications/WHO_CDS_EPR_2007_7.pdf?ua=1.\n198. Deak, C., Relly, C. Tular\u00e4mie auf dem Vormarsch. 2020 10.08.2020 [cited 2021 30.10.2021]; Available from: https://www.paediatrieschweiz.ch/tularamie-auf-dem-vormarsch/.\n199. Otto, P., et al., Hare-to-human transmission of Francisella tularensis subsp. holarctica, Germany. Emerg Infect Dis, 2015. 21(1): p. 153-5.\n200. Sch\u00e4tzle, W. and R. Schwenk, Three cases of tularaemia in southern Baden-Wuerttemberg, Germany, November 2007. Euro Surveill, 2008. 13(7).\n201. Bundesamt f\u00fcr Gesundheit (BAG), Zecken\u00fcbertragene Krankheiten - Lagebericht Schweiz. BAG-Bulletin, 2021. 33/2021.\n202. Reintjes, R., et al., Tularemia outbreak investigation in Kosovo: case control and environmental studies. Emerg Infect Dis, 2002. 8(1): p. 69-73.\n203. Leeflang, M.M., et al., The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. BMC Infect Dis, 2016. 16: p. 140.\n204. Hansen, K. and E. Asbrink, Serodiagnosis of erythema migrans and acrodermatitis chronica atrophicans by the Borrelia burgdorferi flagellum enzyme-linked immunosorbent assay. J Clin Microbiol, 1989. 27(3): p. 545-51.\n205. Branda, J.A., et al., Performance of United States serologic assays in the diagnosis of Lyme borreliosis acquired in Europe. Clin Infect Dis, 2013. 57(3): p. 333-40.\n206. Wilske, B., Epidemiology and diagnosis of Lyme borreliosis. Ann Med, 2005. 37(8): p. 568-79.\n207. Jones, K.L., et al., Strong IgG antibody responses to Borrelia burgdorferi glycolipids in patients with Lyme arthritis, a late manifestation of the infection. Clin Immunol, 2009. 132(1): p. 93-102.\n208. Centers for Disease Control and Prevention (CDC), Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep, 1995. 44(31): p. 590-1.\n209. Wormser, G.P., et al., A limitation of 2-stage serological testing for Lyme disease: enzyme immunoassay and immunoblot assay are not independent tests. Clin Infect Dis, 2000. 30(3): p. 545-8.\n210. Aguero-Rosenfeld, M.E., et al., Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol, 1996. 34(1): p. 1-9.\n211. Altpeter, E.S. and C. Meier, [Epidemiological aspects of neurological complications of Lyme borreliosis in Switzerland. A case-control study]. Schweiz Med Wochenschr, 1992. 122(1-2): p. 22-6.\n212. Nadal, D., et al., Prevalence of antibodies to Borrelia burgdorferi in forestry workers and blood donors from the same region in Switzerland. Eur J Clin Microbiol Infect Dis, 1989. 8(11): p. 992-5.\n213. Porwancher, R.B., et al., Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics. Clin Vaccine Immunol, 2011. 18(5): p. 851-9.\n214. Schoen, R.T., Editorial commentary: better laboratory testing for Lyme disease: no more Western blot. Clin Infect Dis, 2013. 57(3): p. 341-3.\n215. Markowicz, M., D. Kivaranovic, and G. Stanek, Testing patients with non-specific symptoms for antibodies against Borrelia burgdorferi sensu lato does not provide useful clinical information about their aetiology. Clin Microbiol Infect, 2015. 21(12): p. 1098-103.\n216. Branda, J.A., et al., 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin Infect Dis, 2010. 50(1): p. 20-6.\n217. Steere, A.C., et al., Asymptomatic infection with Borrelia burgdorferi. Clin Infect Dis, 2003. 37(4): p. 528-32.\n218. American College of Physicians, Guidelines for laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med, 1997. 127(12): p. 1106-8.\n219. Tugwell, P., et al., Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med, 1997. 127(12): p. 1109-23.\n220. Wormser, G.P., et al., The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis, 2006. 43(9): p. 1089-134.\n221. Wilske, B., V. Fingerle, and U. Schulte-Spechtel, Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol, 2007. 49(1): p. 13-21.\n222. Dressler, F., N.H. Yoshinari, and A.C. Steere, The T-cell proliferative assay in the diagnosis of Lyme disease. Ann Intern Med, 1991. 115(7): p. 533-9.\n223. Huppertz, H.I., et al., Lymphoproliferative responses to Borrelia burgdorferi in the diagnosis of Lyme arthritis in children and adolescents. Eur J Pediatr, 1996. 155(4): p. 297-302.\n224. Zoschke, D.C., A.A. Skemp, and D.L. Defosse, Lymphoproliferative responses to Borrelia burgdorferi in Lyme disease. Ann Intern Med, 1991. 114(4): p. 285-9.\n225. Dessau, R.B., et al., The lymphocyte transformation test for the diagnosis of Lyme borreliosis has currently not been shown to be clinically useful. Clin Microbiol Infect, 2014. 20(10): p. O786-7.\n226. Krause, A., et al., T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis. Autologous serum required for optimum stimulation. Arthritis Rheum, 1991. 34(4): p. 393-402.\n227. Steere, A.C., et al., Lyme borreliosis. Nat Rev Dis Primers, 2016. 2: p. 16090.\n228. Kortela, E., et al., Oral Doxycycline Compared to Intravenous Ceftriaxone in the Treatment of Lyme Neuroborreliosis: A Multicenter, Equivalence, Randomized, Open-label Trial. Clin Infect Dis, 2021. 72(8): p. 1323-1331.\n229. Lj\u00f8stad, U., et al., Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol, 2008. 7(8): p. 690-5.\n230. Smith, G.N., et al., Committee Opinion No. 399: Management of Tick Bites and Lyme Disease During Pregnancy. J Obstet Gynaecol Can, 2020. 42(5): p. 644-653.\n231. National Institute for Health and Care Excellence (NICE). Lyme disease (NG95). 2018 [cited 2021; Available from: https://www.nice.org.uk/guidance/ng95/chapter/Recommendations.\n232. Maraspin, V., et al., Early Lyme Borreliosis in Patients Treated with Tumour Necrosis Factor-Alfa Inhibitors. J Clin Med, 2019. 8(11).\n233. Maraspin, V., et al., Erythema migrans in the immunocompromised host. Wien Klin Wochenschr, 1999. 111(22-23): p. 923-32.\n234. Maraspin, V., et al., Erythema Migrans: Course and Outcome in Patients Treated With Rituximab. Open Forum Infect Dis, 2019. 6(7): p. ofz292.\n235. Nadelman, R.B., et al., Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med, 2012. 367(20): p. 1883-90.\n236. Steere, A.C., Reinfection versus relapse in Lyme disease. N Engl J Med, 2012. 367(20): p. 1950-1.\n237. Baldovin, T., et al., Persistence of immunity to tick-borne encephalitis after vaccination and natural infection. J Med Virol, 2012. 84(8): p. 1274-8.\n238. Remoli, M.E., et al., Anti-tick-borne encephalitis (TBE) virus neutralizing antibodies dynamics in natural infections versus vaccination. Pathog Dis, 2015. 73(2): p. 1-3.\n239. Kaiser, R., et al. Fr\u00fchsommer-Meningoenzephalitis (FSME), S1-Leitlinie. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie 2020 [cited 2021 26.10.2021]; Available from: https://www.awmf.org/uploads/tx_szleitlinien/030-035l_S1_Fruehsommer_Meningoenzephalitis_FSME_2020-02.pdf.\n240. Ursinus, J., et al., Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study. Lancet Reg Health Eur, 2021. 6: p. 100142.\n241. Berende, A., et al., Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. N Engl J Med, 2016. 374(13): p. 1209-20.\n242. Wormser, G.P., et al., Long-term assessment of fatigue in patients with culture-confirmed Lyme disease. Am J Med, 2015. 128(2): p. 181-4.\n243. Strle, K., et al., Elevated levels of IL-23 in a subset of patients with post-lyme disease symptoms following erythema migrans. Clin Infect Dis, 2014. 58(3): p. 372-80.\n244. Fitzgerald, B.L., et al., Metabolic Response in Patients With Post-treatment Lyme Disease Symptoms/Syndrome. Clin Infect Dis, 2021. 73(7): p. e2342-e2349.\n245. Buchwald, D.S., et al., Acute infectious mononucleosis: characteristics of patients who report failure to recover. Am J Med, 2000. 109(7): p. 531-7.\n246. Salit, I.E., Precipitating factors for the chronic fatigue syndrome. J Psychiatr Res, 1997. 31(1): p. 59-65.\n247. Katon, W., et al., Infectious mononucleosis: psychological symptoms during acute and subacute phases of illness. Gen Hosp Psychiatry, 1999. 21(1): p. 21-9.\n248. Hassett, A.L., et al., Role of psychiatric comorbidity in chronic Lyme disease. Arthritis Rheum, 2008. 59(12): p. 1742-9.\n249. Clark, L.V., et al., Guided graded exercise self-help plus specialist medical care versus specialist medical care alone for chronic fatigue syndrome (GETSET): a pragmatic randomised controlled trial. Lancet, 2017. 390(10092): p. 363-373.\n250. Clauw, D.J., Guided graded exercise self-help as a treatment of fatigue in chronic fatigue syndrome. Lancet, 2017. 390(10092): p. 335-336.\n251. Bidonde, J., et al., Aerobic exercise training for adults with fibromyalgia. Cochrane Database Syst Rev, 2017. 6(6): p. Cd012700.\n252. Larun, L., et al., Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev, 2015(2): p. Cd003200.\n253. Bidonde, J., et al., Mixed exercise training for adults with fibromyalgia. Cochrane Database Syst Rev, 2019. 5(5): p. Cd013340.\n254. Busch, A.J., et al., Resistance exercise training for fibromyalgia. Cochrane Database Syst Rev, 2013. 2013(12): p. Cd010884.\n255. Kim, S.Y., et al., Flexibility exercise training for adults with fibromyalgia. Cochrane Database Syst Rev, 2019. 9(9): p. Cd013419.\n256. Theadom, A., et al., Mind and body therapy for fibromyalgia. Cochrane Database Syst Rev, 2015(4): p. Cd001980.\n257. Bidonde, J., et al., Aquatic exercise training for fibromyalgia. Cochrane Database Syst Rev, 2014(10): p. Cd011336.\n258. Klempner, M.S., et al., Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med, 2001. 345(2): p. 85-92.\n259. Krupp, L.B., et al., Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology, 2003. 60(12): p. 1923-30.\n260. Fallon, B.A., et al., A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology, 2008. 70(13): p. 992-1003.\n261. Berende, A., et al., Persistent Lyme Empiric Antibiotic Study Europe (PLEASE)--design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis. BMC Infect Dis, 2014. 14: p. 543.\n262. Goodlet, K.J. and K.A. Fairman, Adverse Events Associated With Antibiotics and Intravenous Therapies for Post-Lyme Disease Syndrome in a Commercially Insured Sample. Clin Infect Dis, 2018. 67(10): p. 1568-1574.\n263. Burrascano JR., J. Advanced topics in lyme disease - Diagnostic hints and treatment guidelines for lyme and other tick borne illnesses. 2008 [cited 2021 21.09.2021]; 16 [Available from: https://www.lymenet.org/BurrGuide200810.pdf.\n264. International Lyme and Associated Disease Society (ILADS). ILADS Positionspapier: Kritik der Studie zur antibiotischen Behandlung der chronischen Lyme-Borreliose. 2002 09.01.2002 [cited 2021 21.09.2021]; Available from: http://www.zeckenliga.ch/wissen/medizinisches-forum/position-ilads/index.html.\n265. Shor, S., et al., Chronic Lyme Disease: An Evidence-Based Definition by the ILADS Working Group. Antibiotics (Basel), 2019. 8(4).", "language": null, "image": null, "pagetype": "article", "links": ["https://www.swisshealthweb.ch/de/newsfeed/", "https://phc.swisshealthweb.ch/de/", "#collapseSearch", "/de/article/doi/phc-d.2022.10573/", "/fr/article/doi/phc-f.2022.10573/", "https://www.swisshealthweb.ch/de/newsfeed/", "https://phc.swisshealthweb.ch/de/", "/de/", "/de/aktuelle-ausgabe/", "/de/archiv/", "/de/publizieren/", "/de/ueber-phc/", "https://www.swisshealthweb.ch/de/zeitschriften/", "https://shop.emh.ch/", "https://www.swisshealthweb.ch/de/encyclomed/", "https://events.emh.ch", "https://phc.swisshealthweb.ch/de/article/?tx_cs2services_teaser%5Baction%5D=serviceLinkHandler&tx_cs2services_teaser%5Bcontroller%5D=Services&tx_cs2services_teaser%5Bservice%5D=9&type=96529&cHash=957c22557b087f72957914479c8387b5", "https://jobs.saez.ch/de", "https://market.swisshealthweb.ch/de/", null, "tel:+410614678555", "#", "https://www.swisshealthweb.ch/de/newsfeed/", "/de/article/doi/phc-d.2022.10573/", "/fr/article/doi/phc-f.2022.10573/", "https://events.emh.ch/", "https://jobs.saez.ch/de", "https://market.swisshealthweb.ch/de/", "https://shop.emh.ch/", null, "javascript:void(0)", "https://phc.swisshealthweb.ch/fileadmin/assets/PHC/2022/phc-d.2022.10573/phc-d-2022-10573.pdf", "#otherInfos", "/de/archiv/ausgabe/issue-doi/phc.2022.04/", "https://doi.org/10.4414/phc-d.2022.10573", "javascript:void(0)", "https://phc.swisshealthweb.ch/fileadmin/assets/PHC/2022/phc-d.2022.10573/phc-d-2022-10573.pdf", "https://emh.ch/en/emh/rights-and-licences/", "#top", null, null, "tel:+410614678555", "#", "https://www.swisshealthweb.ch/de/newsfeed/", "https://www.swisshealthweb.ch/de/informationen-und-services/qualitaetssicherung/", "https://www.swisshealthweb.ch/de/informationen-und-services/publizistische-leitlinien/", "https://www.swisshealthweb.ch/de/informationen-und-services/copyright/", "https://www.swisshealthweb.ch/de/informationen-und-services/newsletter/", "https://www.swisshealthweb.ch/de/verlag/ueber-emh/", "https://www.swisshealthweb.ch/de/verlag/inserieren/", "https://www.swisshealthweb.ch/de/verlag/jobs/", "https://www.swisshealthweb.ch/de/partner/", "https://www.swisshealthweb.ch/de/verlag/hilfe-und-kontakt/", "https://www.swisshealthweb.ch/de/agb/", "https://www.swisshealthweb.ch/de/verlag/impressum/", "https://www.swisshealthweb.ch/de/verlag/datenschutz/", "https://www.swisshealthweb.ch/de/verlag/disclaimer/", "javascript:void()"]}